Retinal Venous Occlusions: Diagnosis and Choice of Treatments

Querques, Giuseppe; Triolo, Giacinto; Casalino, Giuseppe; García‐Arumí, José; Badal, Josep; Zapata, Miguel Á.; Boixadera, Anna; Castillo, Vicente Martínez; Bandello, Francesco

doi:10.1159/000346734

Cited by 13 publications

(14 citation statements)

References 125 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is marked controversy on their pathogeneses, clinical features and particularly their management. Recently, advances in clinical research added anti-VEGF, corticosteroids and sustained-release implants to our armamentarium in the management of retinal vein occlusions [1]. Despite the existence of several therapeutic options, none is entirely satisfactory.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Study of Sulfotanshinone Sodium Injection in Treating Non-Ischemic Retinal Vein Occlusion

Lu¹,

Wu²

2015

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…with significant morbidity, including branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) as well as their ischemic and non-ischemic subtypes [1]. Major causes of vision loss include macular edema and neovascularization with secondary vitreous hemorrhage and/or neovascular glaucoma [2].…”

mentioning

confidence: 99%

Clinical Study of Sulfotanshinone Sodium Injection in Treating Non-Ischemic Retinal Vein Occlusion

Lu¹,

Wu²

2015

View full text Add to dashboard Cite

“…The high number of injections needed with the anti-VEGF is in balance with the incidence of dexamethasone-induced ocular adverse events [47]. At this time, results of head-to-head studies comparing both therapies are pending.…”

Section: Discussionmentioning

confidence: 99%

Intravitreal Ranibizumab and/or Dexamethasone Implant for Macular Edema Secondary to Retinal Vein Occlusion

Nghiem-Buffet

Fajnkuchen²,

Buffet³

et al. 2014

Ophthalmologica

View full text Add to dashboard Cite

Purpose: To investigate the outcome of intravitreal ranibizumab and/or dexamethasone implant treatment for treatment of macular edema (ME) secondary to central or branch retinal vein occlusion (CRVO or BRVO) in a clinical setting. Methods: Retrospective analysis of consecutive patients followed for at least 6 months. Data recorded included the type of occlusion, initial and final visual acuity, and number of injections. Results: Sixty-five patients were included, 26 had CRVO and 39 BRVO. Mean (±SD) follow-up duration was 16 (±7.7) months. Twenty-four (36.9%) patients received ranibizumab in monotherapy, 19 patients (29.3%) dexamethasone in monotherapy, and 22 patients (33.8%) received successively both treatments. In dexamethasone-treated patients, mean (±SD) visual acuity gain was 5.8 ± 10.7 letters for BRVO and 16.8 ± 15.6 letters for CRVO. In ranibizumab-treated patients, mean (±SD) visual acuity gain was 9.2 ± 10 letters for BRVO and 18.2 ± 20.5 letters for CRVO. Conclusion: Both intravitreal ranibizumab and dexamethasone intravitreal implant could be used as first-line therapy for patients with ME secondary to retinal vein occlusion.

show abstract

“…24 BRVO is characterized by occlusion at the level of only one branch of the central retinal vein, either at the level of the macula or the peripheral retina. 25 The occlusion occurs at the crossing point of the artery with a vein, leading to the formation of a thrombus, with damage to endothelial cells and vessel wall. 23,25,26 CRVO, on the other hand, is observed when occlusion affects the entire central retinal vein, involving the central retinal artery, the central retinal vein and the optic nerve.…”

Section: Retinal Vein Occlusionmentioning

confidence: 99%

Vascular Regeneration for Ischemic Retinopathies: Hope from Cell Therapies

Bertelli

Pedrini

Guduric-Fuchs

et al. 2019

Current Eye Research

View full text Add to dashboard Cite

Retinal vascular diseases, such as diabetic retinopathy, retinopathy of prematurity, retinal vein occlusion, ocular ischemic syndrome and ischemic optic neuropathy, are leading causes of vision impairment and blindness. Whilst drug, laser or surgery-based treatments for the late stage complications of many of these diseases are available, interventions that target the early vasodegenerative stages are lacking. Progressive vasculopathy and ensuing ischemia is an underpinning pathology in many of these diseases, leading to hypoperfusion, hypoxia, and ultimately pathological neovascularization and/or edema in the retina and other ocular tissues, such as the optic nerve and iris. Therefore, repairing the retinal vasculature may prevent progression of ischemic retinopathies into late stage vascular complications. Various cell types have been explored for their vascular repair potential. Endothelial progenitor cells, mesenchymal stem cells and induced pluripotent stem cells are studied for their potential to integrate with the damaged retinal vasculature and limit ischemic injury. Clinical trials for some of these cell types have confirmed safety and feasibility in the treatment of ischemic diseases, including some retinopathies. Another promising avenue is mobilization of endogenous endothelial progenitors, whereby reparative cells are moved from their niche to circulating blood to target and home into ischemic tissues. Several aspects and properties of these cell types have yet to be elucidated. Nevertheless, we foresee that cell therapy, whether through delivery of exogenous or enhancement of endogenous reparative cells, will become a valuable and beneficial treatment for ischemic retinopathies. ARTICLE HISTORY

show abstract

Retinal Venous Occlusions: Diagnosis and Choice of Treatments

Cited by 13 publications

References 125 publications

Clinical Study of Sulfotanshinone Sodium Injection in Treating Non-Ischemic Retinal Vein Occlusion

Clinical Study of Sulfotanshinone Sodium Injection in Treating Non-Ischemic Retinal Vein Occlusion

Intravitreal Ranibizumab and/or Dexamethasone Implant for Macular Edema Secondary to Retinal Vein Occlusion

Vascular Regeneration for Ischemic Retinopathies: Hope from Cell Therapies

Contact Info

Product

Resources

About